JP7377901B2 - 疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 - Google Patents
疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 Download PDFInfo
- Publication number
- JP7377901B2 JP7377901B2 JP2022040883A JP2022040883A JP7377901B2 JP 7377901 B2 JP7377901 B2 JP 7377901B2 JP 2022040883 A JP2022040883 A JP 2022040883A JP 2022040883 A JP2022040883 A JP 2022040883A JP 7377901 B2 JP7377901 B2 JP 7377901B2
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- enzyme
- lipoproteins
- fluid
- assay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000003556 assay Methods 0.000 title claims description 53
- 238000000034 method Methods 0.000 title claims description 38
- 230000002209 hydrophobic effect Effects 0.000 title claims description 32
- 108090001030 Lipoproteins Proteins 0.000 title claims description 29
- 102000004895 Lipoproteins Human genes 0.000 title claims description 29
- 239000000203 mixture Substances 0.000 title description 12
- 238000000338 in vitro Methods 0.000 title description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 62
- 239000012491 analyte Substances 0.000 claims description 34
- 102000004190 Enzymes Human genes 0.000 claims description 25
- 108090000790 Enzymes Proteins 0.000 claims description 25
- 239000012530 fluid Substances 0.000 claims description 19
- 239000012472 biological sample Substances 0.000 claims description 16
- 239000000523 sample Substances 0.000 claims description 15
- 102000004882 Lipase Human genes 0.000 claims description 11
- 108090001060 Lipase Proteins 0.000 claims description 11
- 239000004367 Lipase Substances 0.000 claims description 11
- 235000019421 lipase Nutrition 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 8
- 229960005167 everolimus Drugs 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 7
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 229940011871 estrogen Drugs 0.000 claims description 6
- 239000000262 estrogen Substances 0.000 claims description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 6
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 239000003613 bile acid Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000003018 immunoassay Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229960001967 tacrolimus Drugs 0.000 claims description 5
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 4
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 4
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 229930182833 estradiol Natural products 0.000 claims description 4
- 229960005309 estradiol Drugs 0.000 claims description 4
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 4
- 229960001348 estriol Drugs 0.000 claims description 4
- 229960003399 estrone Drugs 0.000 claims description 4
- 210000003722 extracellular fluid Anatomy 0.000 claims description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 3
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 claims description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 3
- ZGLHBRQAEXKACO-XJRQOBMKSA-N 1alpha,25-dihydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C ZGLHBRQAEXKACO-XJRQOBMKSA-N 0.000 claims description 3
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 claims description 3
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 claims description 3
- KJKIIUAXZGLUND-ICCVIKJNSA-N 25-hydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-ICCVIKJNSA-N 0.000 claims description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 3
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 3
- MTMZZIPTQITGCY-OLGWUGKESA-N Moxestrol Chemical compound OC1=CC=C2[C@H]3[C@@H](OC)C[C@]4(C)[C@@](C#C)(O)CC[C@H]4[C@@H]3CCC2=C1 MTMZZIPTQITGCY-OLGWUGKESA-N 0.000 claims description 3
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229960002478 aldosterone Drugs 0.000 claims description 3
- -1 alpha-tradiol Natural products 0.000 claims description 3
- 239000003098 androgen Substances 0.000 claims description 3
- 229940030486 androgens Drugs 0.000 claims description 3
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims description 3
- 229960005084 calcitriol Drugs 0.000 claims description 3
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 3
- 150000003943 catecholamines Chemical class 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 210000002726 cyst fluid Anatomy 0.000 claims description 3
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 3
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 229960002568 ethinylestradiol Drugs 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 229960001241 moxestrol Drugs 0.000 claims description 3
- 210000003097 mucus Anatomy 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- 239000000583 progesterone congener Substances 0.000 claims description 3
- PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 claims description 3
- 229960001424 quinestrol Drugs 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000004243 sweat Anatomy 0.000 claims description 3
- 229960003604 testosterone Drugs 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- 210000001138 tear Anatomy 0.000 claims description 2
- 229960005471 androstenedione Drugs 0.000 claims 2
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 17
- 235000012000 cholesterol Nutrition 0.000 description 12
- 230000027455 binding Effects 0.000 description 8
- 238000004891 communication Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000002934 lysing effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229920001400 block copolymer Polymers 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 3
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- KJKIIUAXZGLUND-QVKZFZTCSA-N (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(e,2r,5r)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-QVKZFZTCSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010046315 IDL Lipoproteins Proteins 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229920000344 molecularly imprinted polymer Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/16—Reagents, handling or storing thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/087—Multiple sequential chambers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/918—Carboxylic ester hydrolases (3.1.1)
- G01N2333/92—Triglyceride splitting, e.g. by means of lipase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Clinical Laboratory Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Fluid Mechanics (AREA)
- Ecology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Description
該当しない。
該当しない。
れる用語に応じて、最大100または1000もしくはそれ以上に拡張されることがあり;加えて、100/1000の数量は、それより多い制限値も満足する結果をもたらすことがあるので、限定的なものと考えるべきではない。加えて、「X、Y、およびZのうち少なくとも1つ」という用語の使用は、X単独、Y単独、およびZ単独、ならびにX、Y、およびZの任意の組合せを含むものと理解される。序数の用語(すなわち、「第1の」、「第2の」、「第3の」、「第4の」など)の使用は、単に2つ以上の項目を区別するためのものであり、例えば、1つの項目の別の項目に対する任意の順序もしくは順番もしくは重要性または任意の追加の順序を含意することを意図するものではない。
CB、BAC、またはCABも含むものとする。この例を続けると、BB、AAA、AAB、BBC、AAABCCCC、CBBAAA、およびCABABBなどのような、1つまたはそれ以上の項目または用語の繰り返しを含む組合せが明らかに含まれる。当業者は、文脈からそうでないことが明白でない限り、通常、任意の組合せにおいて項目または用語の数に限定がないことを理解されよう。
なわち、これらに限定されないが、標的分析物を特異的に認識する抗体など)に接近可能になる。このため、標的分析物は、前処理試薬が利用されていないアッセイと比較して高効率で検出され、それによって影響をより受けにくい標的分析物のアッセイがもたらされる。
L、約0.3mg/mL、約0.4mg/mL、約0.5mg/mL、約0.6mg/mL、約0.7mg/mL、約0.8mg/mL、約0.9mg/mL、約1mg/mL、約1.5mg/mL、約2mg/mL、約2.5mg/mL、約3mg/mL、約3.5mg/mL、約4mg/mL、約4.5mg/mL、約5mg/mL、約5.5mg/mL、約6mg/mL、約6.5mg/mL、約7mg/mL、約7.5mg/mL、約8mg/mL、約8.5mg/mL、約9mg/mL、約9.5mg/mL、約10mg/mL、約11mg/mL、約12mg/mL、約13mg/mL、約14mg/mL、約15mg/mL、約16mg/mL、約17mg/mL、約18mg/mL、約19mg/mL、約20mg/mL、約21mg/mL、約22mg/mL、約23mg/mL、約24mg/mL、約25mg/mL、約26mg/mL、約27mg/mL、約28mg/mL、約29mg/mL、約30mg/mL、約31mg/mL、約32mg/mL、約33mg/mL、約34mg/mL、約35mg/mL、約36mg/mL、約37mg/mL、約38mg/mL、約39mg/mL、約40mg/mL、約41mg/mL、約42mg/mL、約43mg/mL、約44mg/mL、約45mg/mL、約46mg/mL、約47mg/mL、約48mg/mL、約49mg/mL、約50mg/mL、約55mg/mL、約60mg/mL、約65mg/mL、約70mg/mL、約75mg/mL、約80mg/mL、約85mg/mL、約90mg/mL、約95mg/mL、約100mg/mL、またはそれ以上が含まれるが、それだけには限定されない。特定の(しかし非限定的な)実施形態では、前処理試薬中の酵素の濃度は、上記の値のいずれか2つの範囲、例えば(これらに限定されないが)約0.01mg/mL~約100mg/mLの範囲、約0.05mg/mL~約50mg/mLの範囲、約0.1mg/mL~約20mg/mLの範囲、約0.5mg/mL~約10mg/mLの範囲などの範囲内にあると定義される。しかし、上記の特定の濃度範囲は、例示の目的のみのためのものであり、限定的とみなすべきではなく;上記の値の1つの下限値および上記の別の値の上限値を有する任意の濃度範囲は、本開示の範囲内に明示的に含まれることを理解されたい。
ントへと移され、その後試料を前処理工程の前処理試薬とインキュベートすることができる。
Claims (11)
- 生物学的試料中の標的疎水性分析物の存在および/または濃度を検出する方法であって:
同時に、または全体的にもしくは部分的に連続して:
(1)該標的疎水性分析物を含むことが疑われる試料;
(2)リポタンパク質を消化する少なくとも1つの酵素を含む前処理試薬;および
(3)疎水性分析物を検出することが可能な少なくとも1つのアッセイ試薬
を組み合わせる工程、ならびに
1つまたはそれ以上の(3)に基づく検出アッセイを実行し、該試料中に存在する標的疎水性分析物の濃度を決定する工程
を含み、
リポタンパク質を消化する少なくとも1つの酵素は、リパーゼを含み、
標的疎水性分析物は、ビタミンD、タクロリムス、シロリムス、エベロリムス、エストロゲン、エストロン、エストラジオール、エストリオール、アルファトラジオール、シクロスポリン、エチニルエストラジオール、エステル化エストロゲン、モキセストロール、キネストロール、プロゲスチン、プロゲステロン、アンドロゲン、テストステロン、ジヒドロテストステロン(DHT)、デヒドロエピアンドロステロン(DHEA)、硫酸DHEA、アンドロステンジオン、アルドステロン、コルチゾール、カテコールアミン、25-ヒドロキシビタミンD2、25-ヒドロキシビタミンD3、1,25-ジヒドロキシビタミンD2、および1,25-ジヒドロキシビタミンD3からなる群から選択される、前記方法。 - 酵素が、0.1mg/mL~20mg/mLの範囲の濃度で前処理試薬中に存在する、請求項1に記載の方法。
- 前処理試薬が、酵素の補助因子、界面活性剤、プロテアーゼ、およびその組合せからなる群から選択される少なくとも1つの追加物質をさらに含む、請求項1に記載の方法。
- リポタンパク質を消化する少なくとも1つの酵素がリパーゼであり、前処理試薬が、リ
パーゼの補助因子として胆汁酸および/またはその塩を含む、請求項3に記載の方法。 - 少なくとも1つのアッセイ試薬が、さらに免疫アッセイ試薬と定義される、請求項1に記載の方法。
- 試料が、尿、全血またはその任意の部分、溶解された血液またはその任意の部分、唾液、痰、脳脊髄液(CSF)、腸液、腹腔内液、嚢胞液、汗、間質液、涙液、粘液、膀胱洗浄液、精液、およびその任意の組合せからなる群から選択される生物学的試料である、請求項1に記載の方法。
- 生物学的試料中の標的疎水性分析物の存在および/または濃度を検出する方法に使用するためのキットであって:
リポタンパク質を消化する少なくとも1つの酵素を含む前処理試薬;および
該試料中に存在する標的疎水性分析物の濃度を決定するための、疎水性分析物を検出することが可能な少なくとも1つのアッセイ試薬
を含み、
リポタンパク質を消化する少なくとも1つの酵素は、リパーゼを含み、
標的疎水性分析物は、ビタミンD、タクロリムス、シロリムス、エベロリムス、エストロゲン、エストロン、エストラジオール、エストリオール、アルファトラジオール、シクロスポリン、エチニルエストラジオール、エステル化エストロゲン、モキセストロール、キネストロール、プロゲスチン、プロゲステロン、アンドロゲン、テストステロン、ジヒドロテストステロン(DHT)、デヒドロエピアンドロステロン(DHEA)、硫酸DHEA、アンドロステンジオン、アルドステロン、コルチゾール、カテコールアミン、25-ヒドロキシビタミンD2、25-ヒドロキシビタミンD3、1,25-ジヒドロキシビタミンD2、および1,25-ジヒドロキシビタミンD3からなる群から選択される、前記キット。 - リポタンパク質を消化する少なくとも1つの酵素は、0.1mg/mL~20mg/mLの範囲の濃度で前処理試薬中に存在する、請求項7に記載のキット。
- 前処理試薬が、酵素の補助因子、界面活性剤、プロテアーゼ、およびその組合せからなる群から選択される少なくとも1つの追加物質をさらに含む、請求項7に記載のキット。
- リポタンパク質を消化する少なくとも1つの酵素がリパーゼであり、ここで前処理試薬が、リパーゼの補助因子として胆汁酸および/またはその塩を含む、請求項9に記載のキット。
- 少なくとも1つのアッセイ試薬が、さらに免疫アッセイ試薬と定義される、請求項9に記載のキット。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023182232A JP2024010075A (ja) | 2019-03-19 | 2023-10-24 | 疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962820409P | 2019-03-19 | 2019-03-19 | |
US62/820,409 | 2019-03-19 | ||
PCT/US2020/013629 WO2020190358A1 (en) | 2019-03-19 | 2020-01-15 | Compositions, devices, and methods of mitigating lipoprotein interference in in vitro diagnostic assays for hydrophobic analytes |
JP2021556430A JP7044948B1 (ja) | 2019-03-19 | 2020-01-15 | 疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021556430A Division JP7044948B1 (ja) | 2019-03-19 | 2020-01-15 | 疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023182232A Division JP2024010075A (ja) | 2019-03-19 | 2023-10-24 | 疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022078307A JP2022078307A (ja) | 2022-05-24 |
JP7377901B2 true JP7377901B2 (ja) | 2023-11-10 |
Family
ID=72521061
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021556430A Active JP7044948B1 (ja) | 2019-03-19 | 2020-01-15 | 疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 |
JP2022040883A Active JP7377901B2 (ja) | 2019-03-19 | 2022-03-16 | 疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 |
JP2023182232A Pending JP2024010075A (ja) | 2019-03-19 | 2023-10-24 | 疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021556430A Active JP7044948B1 (ja) | 2019-03-19 | 2020-01-15 | 疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023182232A Pending JP2024010075A (ja) | 2019-03-19 | 2023-10-24 | 疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US11358143B2 (ja) |
EP (2) | EP4379384A2 (ja) |
JP (3) | JP7044948B1 (ja) |
CN (2) | CN115418389A (ja) |
WO (1) | WO2020190358A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022259890A1 (ja) | 2021-06-10 | 2022-12-15 | 恵和株式会社 | 光拡散シート、光拡散シート積層体、バックライトユニット、及び液晶表示装置 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002090365A (ja) | 2000-02-08 | 2002-03-27 | Internatl Reagents Corp | 腎障害の検査手段 |
JP2005503534A (ja) | 2001-01-16 | 2005-02-03 | クエスト ダイアグノスティクス インコーポレイテッド | ビタミンdアッセイ |
JP2005514929A (ja) | 2002-01-10 | 2005-05-26 | テバ ファーマシューティカル インダストリーズ リミティド | エピマービタミンd類似物の酵素による選択的なエステル化及び加溶媒分解及びエピマーの分離 |
JP2009520974A (ja) | 2005-12-21 | 2009-05-28 | オックスフォード バイオセンサーズ リミテッド | コレステロールセンサー |
JP2010518369A (ja) | 2007-02-01 | 2010-05-27 | イムンディアグノスティック アクチェンゲゼルシャフト | 血清あるいは血漿中のビタミンdの直接決定 |
WO2014122972A1 (ja) | 2013-02-06 | 2014-08-14 | 富士レビオ株式会社 | ビタミンdの測定方法および測定用キット |
US20170168077A1 (en) | 2015-12-11 | 2017-06-15 | Opko Diagnostics, Llc | Fluidic systems involving incubation of samples and/or reagents |
JP2018501485A (ja) | 2014-12-17 | 2018-01-18 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドSiemens Healthcare Diagnostics Inc. | 疎水性ハプテン被検体の正確なアッセイ測定 |
US10073103B1 (en) | 2013-03-11 | 2018-09-11 | Theranos Ip Company, Llc | Rapid measurement of total vitamin D in blood |
CN108918848A (zh) | 2018-05-22 | 2018-11-30 | 德康润生物科技(北京)有限公司 | 维生素d释放剂及其制备方法与应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU771951B2 (en) * | 1999-05-28 | 2004-04-08 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Homogeneous tests for sequentially determining lipoprotein fractions |
US7258990B2 (en) * | 2004-08-19 | 2007-08-21 | Biocept, Inc. | Alleviation of non-specific binding in microarray assays |
GB0609493D0 (en) * | 2006-05-12 | 2006-06-21 | Oxford Biosensors Ltd | Cholesterol sensor |
JP5852781B2 (ja) | 2007-07-31 | 2016-02-03 | マイクロニクス, インコーポレイテッド | 衛生的スワブ採取システム、マイクロ流体アッセイデバイスおよび診断アッセイのための方法 |
JP5823953B2 (ja) * | 2010-03-31 | 2015-11-25 | 積水メディカル株式会社 | 内因性リポ蛋白質の影響回避方法及び試薬 |
US9658218B2 (en) * | 2012-05-07 | 2017-05-23 | Siemens Healthcare Diagnostics Inc. | Determination of total analyte concentration |
US10309921B2 (en) | 2014-03-03 | 2019-06-04 | The Florida International University Board Of Trustees | Label-free electrochemical biosensor |
CN104749009B (zh) | 2015-03-30 | 2018-05-04 | 上海云泽生物科技有限公司 | 用于免疫分析的免疫抑制剂药物提取试剂 |
US20170014822A1 (en) * | 2015-07-15 | 2017-01-19 | Aark Health Private Limited | Microfluidic cartridge and reader device, system, and method of use |
US20170131298A1 (en) * | 2015-11-06 | 2017-05-11 | The Board Of Regents Of The University Of Texas System | Apparatuses, Methods and Compositions for Compound Detection Using Interfacial Nano-Biosensing in Microfluidic Droplets |
CN108627510A (zh) * | 2018-06-06 | 2018-10-09 | 临安卡尔生物技术有限公司 | 高密度脂蛋白胆固醇检测试剂盒 |
-
2020
- 2020-01-15 WO PCT/US2020/013629 patent/WO2020190358A1/en unknown
- 2020-01-15 EP EP24164757.7A patent/EP4379384A2/en active Pending
- 2020-01-15 US US17/310,469 patent/US11358143B2/en active Active
- 2020-01-15 CN CN202211234022.5A patent/CN115418389A/zh active Pending
- 2020-01-15 EP EP20773681.0A patent/EP3941627B1/en active Active
- 2020-01-15 JP JP2021556430A patent/JP7044948B1/ja active Active
- 2020-01-15 CN CN202080022535.2A patent/CN113631272B/zh active Active
-
2022
- 2022-03-16 JP JP2022040883A patent/JP7377901B2/ja active Active
- 2022-05-12 US US17/663,020 patent/US20220387994A1/en active Pending
-
2023
- 2023-10-24 JP JP2023182232A patent/JP2024010075A/ja active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002090365A (ja) | 2000-02-08 | 2002-03-27 | Internatl Reagents Corp | 腎障害の検査手段 |
JP2005503534A (ja) | 2001-01-16 | 2005-02-03 | クエスト ダイアグノスティクス インコーポレイテッド | ビタミンdアッセイ |
JP2005514929A (ja) | 2002-01-10 | 2005-05-26 | テバ ファーマシューティカル インダストリーズ リミティド | エピマービタミンd類似物の酵素による選択的なエステル化及び加溶媒分解及びエピマーの分離 |
JP2009520974A (ja) | 2005-12-21 | 2009-05-28 | オックスフォード バイオセンサーズ リミテッド | コレステロールセンサー |
JP2010518369A (ja) | 2007-02-01 | 2010-05-27 | イムンディアグノスティック アクチェンゲゼルシャフト | 血清あるいは血漿中のビタミンdの直接決定 |
WO2014122972A1 (ja) | 2013-02-06 | 2014-08-14 | 富士レビオ株式会社 | ビタミンdの測定方法および測定用キット |
US10073103B1 (en) | 2013-03-11 | 2018-09-11 | Theranos Ip Company, Llc | Rapid measurement of total vitamin D in blood |
JP2018501485A (ja) | 2014-12-17 | 2018-01-18 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドSiemens Healthcare Diagnostics Inc. | 疎水性ハプテン被検体の正確なアッセイ測定 |
US20170168077A1 (en) | 2015-12-11 | 2017-06-15 | Opko Diagnostics, Llc | Fluidic systems involving incubation of samples and/or reagents |
CN108918848A (zh) | 2018-05-22 | 2018-11-30 | 德康润生物科技(北京)有限公司 | 维生素d释放剂及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113631272B (zh) | 2022-12-20 |
JP2022078307A (ja) | 2022-05-24 |
JP2022521814A (ja) | 2022-04-12 |
US20220387994A1 (en) | 2022-12-08 |
CN113631272A (zh) | 2021-11-09 |
JP2024010075A (ja) | 2024-01-23 |
EP4379384A2 (en) | 2024-06-05 |
EP3941627A1 (en) | 2022-01-26 |
US20220040693A1 (en) | 2022-02-10 |
JP7044948B1 (ja) | 2022-03-30 |
US11358143B2 (en) | 2022-06-14 |
CN115418389A (zh) | 2022-12-02 |
EP3941627A4 (en) | 2022-08-03 |
WO2020190358A1 (en) | 2020-09-24 |
EP3941627B1 (en) | 2024-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2602619B1 (en) | Immunochromatography reagent composition, and measurement method using same | |
EP2174137B1 (en) | Immunoassays exhibiting reduced cross-reactivity with hydrophobic drug analyte metabolites | |
Malheiro et al. | Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation | |
JP2024010075A (ja) | 疎水性分析物のin vitro診断アッセイにおけるリポタンパク質妨害を軽減する組成物、デバイス、および方法 | |
CZ20002606A3 (cs) | Chromatografické zkušební zařízení pro detekci přítomnosti analyzované složky v krevním vzorku | |
EP2955516A1 (en) | Vitamin d measurement method and measurement kit | |
EP2585832B1 (en) | Reduction in false results in assay measurements | |
CN109239367A (zh) | 测定小分子化合物的方法及试剂盒 | |
Sun et al. | A microsphere-based duplex competitive immunoassay for the simultaneous measurements of aldosterone and testosterone in small sample volumes: validation in human and mouse plasma | |
US11768209B2 (en) | Method and reagent for measuring thyroglobulin | |
WO2021139375A1 (zh) | 6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途 | |
EP1861712A2 (en) | Extracting reagent for hydrophobic analyte in whole blood | |
JPWO2008053900A1 (ja) | B型肝炎ウイルスの高感度免疫学的分析方法及び免疫学的分析用試薬 | |
Gori et al. | Addressing Heterogeneity in Direct Analysis of Extracellular Vesicles and Their Analogs by Membrane Sensing Peptides as Pan‐Vesicular Affinity Probes | |
EP3236261B1 (en) | Test strip for use in immunochromatography for detecting analyte in sample containing red blood cells, and immunochromatography using said test strip | |
JP6559135B2 (ja) | 非凝集検定における前処理剤 | |
US8809003B2 (en) | Reduction in false results in assay measurements | |
JP6040595B2 (ja) | ハプテン標準液およびそれを含むハプテン定量試薬 | |
WO2006093224A1 (ja) | 免疫測定法及びその試薬 | |
JP2010025866A (ja) | 非特異反応抑制剤 | |
KR20240051109A (ko) | 검정 신호 증폭을 위한 방법, 조성물 및 키트 | |
WO2023114993A1 (en) | Biotin-trap beads and methods of production and use thereof | |
CN111855991A (zh) | 免疫测定的样本预处理用试剂和样本预处理方法、以及免疫测定用试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220316 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220316 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230224 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230314 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230613 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230822 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231003 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231030 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7377901 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |